Prelude Therapeutics Inc at Bank of America Global Healthcare Conference Transcript
Thank you for the invitation to present. I'm Jane Huang, President and Chief Medical Officer here at Prelude. We're really pleased to be with you today. Just to orient you, we have very deep research routes which has allowed us to develop a highly differentiated pipeline of products. Just the standard disclosures here on this next slide.
And this is our slide about our portfolio and the history behind our company. For those of you in the audience who are new to Prelude, we are a clinical-stage precision oncology company solely focused to discovering and developing innovative small molecule medicines for patients with underserved cancers.
Central to our core mission is our R&D engine that is run by a proven experienced team that has consistently delivered 1 Imd every 12 to 18 months since our inception, and I'm confident that we'll continue to do so in the future.
Our pipeline consists of highly differentiated molecules that were designed and optimized to effectively block key oncogenic
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |